- Research Projects
- Horizon Scanning in Oncology - Reports and Fact Sheets
Horizon Scanning in Oncology - Reports and Fact Sheets
Decision Support Documents
Within the scope of the Horizon Scanning in Oncology project, the LBI-HTA periodically published assessments until 2019 on novel cancer drugs with a likely therapeutical and/or financial outcome. These assessments served as decision aids for funding agencies and the decision-making network "HTA in hospitals " alike.
Since January 2020, monthly Fact Sheets will be conducted concerning all pharmaceutical oncological therapies that have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
Oncology Fact Sheets since January 2020:
Fact Sheet No. 50 (April 2021) New!
Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma
Fact Sheet No. 49 (April 2021) New!
Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML)
Fact Sheet No. 48 (April 2021) New!
Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC)
Fact Sheet No. 47 (April 2021) New!
Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML)
Fact Sheet No. 46 (March 2021)
Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)
Fact Sheet No. 45 (March 2021)
Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)
Fact Sheet No. 44 (March 2021)
Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL)
Fact Sheet No. 43 (February 2021)
Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM)
Fact Sheet No. 42 (February 2021)
Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)
Fact Sheet No. 41 (February 2021)
Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC)
Fact Sheet No. 40 (January 2021)
Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement
Fact Sheet No. 39 (January 2021)
Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM)
Fact Sheet No. 38 (January 2021)
Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL)
Fact Sheet No. 37 (Dezember 2020) Update
Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer
Fact Sheet No. 36 (Dezember 2020)
Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer
Fact Sheet No. 35 (Dezember 2020) Update
Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL)
Fact Sheet No. 34 (Dezember 2020) Update
Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer
Fact Sheet Nr. 33 (Dezember 2020) 2. Update
Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis
Fact Sheet No. 32 (Dezember 2020) Update
Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer
Fact Sheet No. 31 (Dezember 2020) Update
Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma
Fact Sheet No. 30 (November 2020) Update
A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer
Fact Sheet No. 29 (November 2020) Update
Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM)
Fact Sheet No. 28 (November 2020) Update
Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN)
Fact Sheet No. 27 (October 2020) Update
Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL)
Fact Sheet No. 26 (October 2020) Update
Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC)
Fact Sheet No. 25 (October 2020) Update
Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL)
Fact Sheet No. 24 (September 2020) Update
Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer
Fact Sheet No. 23 (September 2020) Update
Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC)
Fact Sheet No. 22 (September 2020) Update
Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer
Fact Sheet No. 21 (September 2020) Update
Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)
Fact Sheet No. 20 (September 2020) Update
Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC)
Fact Sheet No. 19 (Juli 2020) Update
Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)
Fact Sheet No. 18 (Juli 2020) Update
Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)
Fact Sheet No. 17 (Juli 2020) Update
Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM)
Fact Sheet No. 16 (Juli 2020) Update
Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST)
Fact Sheet No. 15 (Juli 2020) Update
Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL)
Fact Sheet No. 14 (ad April 2020)
Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL)
Fact Sheet No. 13 (Mai 2020) Update
Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC
Fact Sheet No. 12 (Mai 2020) Update
Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer
Fact Sheet No. 11 (Mai 2020)
Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer
Fact Sheet No. 10 (April 2020)
Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML)
Fact Sheet No. 9 (April 2020)
Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma
Fact Sheet No. 8 (April 2020) Update
Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen
Fact Sheet No. 7 (April 2020)
Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation
Fact Sheet No. 6 (March 2020)
Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM)
Fact Sheet No. 5 (March 2020)
Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL)
Fact Sheet No. 4 (February 2020)
Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC)
Fact Sheet No. 3 (January 2020)
Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL
Fact Sheet No. 2 (January 2020)
Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC)
Fact Sheet No. 1 (January 2020)
Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions
Publikation series October 2009 - December 2020 (in English):
DSD HSO No. 90
Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)
DSD HSO No. 89
Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs)
DSD HSO No. 88
Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC)
DSD HSO No. 87
Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triple-negative breast cancer (aTNBC)
DSD HSO No. 86
Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer'
DSD HSO No. 85
Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinemia
DSD HSO No. 84
Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC)
DSD HSO No. 83
Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC)
DSD HSO No. 82
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC
DSD HSO No. 81
Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma
DSD HSO No. 80
Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non–small-cell lung cancer (NSCLC)
DSD HSO No. 79
Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)
DSD HSO No. 77
Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)
DSD HSO No. 76
Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy
DSD HSO No. 74
Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukaemia
DSD HSO No. 72
Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC)
DSD HSO No. 71
Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer
DSD HSO No. 70
Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC)
DSD HSO No. 69
Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer
DSD HSO No. 68
Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC)
DSD HSO No. 67
Ipilimumab (Yervoy®) in the adjuvant therapy for high-risk stage III cutaneous melanoma
DSD HSO No. 66
Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy
DSD HSO No. 65
Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer
DSD HSO No. 63
Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM)
DSD HSO No. 62
Venetoclax (VenclextaTM) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion
DSD HSO No. 61
Atezolizumab (TecentriqTM) for the treatment of locally advanced and metastatic urothelial carcinoma
DSD HSO No. 60
Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL)
DSD HSO No. 58
Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC)
DSD HSO No. 57
Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL)
DSD HSO No. 56
Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer
DSD HSO No. 55
Pembrolizumab (Keytruda®) for the treatment of advanced melanoma
DSD HSO No. 53
Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer
DSD HSO No. 52
Carfilzomib (Kyprolis®) for patients with relapsed multiple myeloma who have received one to three prior lines of therapy
DSD HSO No. 50
Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma
DSD HSO No. 49
Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia
DSD HSO No. 48
Bevacizumab (Avastin®) for platinum-resistant recurrent, epithelial ovarian, fallopian tube or primary peritoneal cancer
DSD HSO No. 47
Ibrutinib (Imbruvica®) for relapsed or refractory chronic lymphocytic leukaemia
DSD HSO No. 46
Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma
DSD HSO No. 45
Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL)
DSD HSO No. 43
Nab-Paclitaxel (Abraxane®) as first-line therapy for metastatic adenocarcinoma of the pancreas
DSD HSO No. 40
Regorafenib (Stivarga®) for heavily pretreated patients with metastatic colorectal cancer (mCRC)
DSD HSO No. 39
Pomalidomide (Pomalyst®) for the ? 3rd-line therapy of patients with relapsed and refractory multiple myeloma
DSD HSO No. 38
Aflibercept (Zaltrap®) in addition to FOLFIRI for the 2nd line therapy of metastatic colorectal cancer
DSD HSO No. 36
Trastuzumab emtansine (KadcylaTM) for previously treated patients with
HER2-positive advanced/ metastatic breast cancer
DSD HSO No. 35
Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)
DSD HSO No. 34
Trametinib for advanced or metastatic BRAF V600 mutation-positive melanoma
DSD HSO No. 33
Lenalidomide (Revlimid®) for the first-line therapy of transplant-ineligible patients with multiple myeloma
DSD HSO No. 31
Pertuzumab (Omnitarg/Perjeta®) for the first-line therapy of metastatic HER2 positive breast cancer
DSD HSO No. 30
Ipilimumab (Yervoy®) for the first-line therapy of advanced/metastatic cutaneous melanoma
DSD HSO No. 28
Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion
DSD HSO No. 27
Bevacizumab (Avastin®) in combination with chemotherapy in previously treated metastatic breast cancer
DSD HSO No. 24
Everolimus (Afinitor®) for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin
DSD HSO No. 23
Vemurafenib for patients with BRAF V600E mutation positive advanced/metastatic melanoma
DSD HSO No. 21
Axitinib (AG013736, Inlyta®) for the second-line treatment of metastatic renal cell carcinoma (mRCC)
DSD HSO No. 19
S-1 (TeysunoTM) as first-line therapy for patients with advanced non-small cell lung cancer
DSD HSO No. 18
Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer
DSD HSO No. 17
Dasatinib (Sprycel®) for the 1st-line treatment of Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase
DSD HSO No. 16
Second-line chemotherapy with cabazitaxel (Jevtana®) for the treatment of castration-resistant metastatic prostate cancer
DSD HSO No. 15
Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase
DSD HSO No. 14
Ipilimumab for pre-treated patients with advanced/metastatic melanoma
DSD HSO No. 13
Pazopanib (Votrient®) for the treatment of locally advanced and/or metastatic renal cell carcinoma
DSD HSO No. 12
Trastuzumab (Herceptin®) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer
DSD HSO No. 11
Panitumumab (Vectibix®) for the first-line treatment of metastatic colorectal cancer
DSD HSO No. 11/ 1st update 2011
Panitumumab (Vectibix®) as 1st-line combination therapy for the treatment of WT KRAS metastatic colorectal cancer
DSD HSO No. 9
Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer
DSD HSO No. 8
Plerixafor (Mozobil®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma
DSD HSO No. 7
Trabectedin (Yondelis®) for second-line recurrent platinum-sensitive ovarian cancer
DSD HSO No. 6
Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer
DSD HSO No. 6/ 1st update 2011
Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung cancer – 1st Update 2011
DSD HSO No. 5
Ibritumomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma
DSD HSO No. 4
Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia
DSD HSO No.4/ 1st update 2011
Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia – 1st Update 2011
DSD HSO No. 3
Everolimus (Afinitor®) for the treatment of advanced/metastatic kidney cancer
DSD HSO No. 2
Cetuximab (Erbitux®) in EGFR-expressing Non-Small Cell Lung Cancer
DSD HSO No. 1
Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes
Contact: Nicole Grössmann
